- Open Access
Gentisic acid sodium salt, a phenolic compound, is superior to norepinephrine in reversing cardiovascular collapse, hepatic mitochondrial dysfunction and lactic acidemia in Pseudomonas aeruginosa septic shock in dogs
© The Author(s). 2016
- Received: 16 February 2016
- Accepted: 7 July 2016
- Published: 26 July 2016
The development of lactic acidemia (LA) in septic shock (SS) is associated with an ominous prognosis. We previously showed that the mechanism of LA in SS may relate to impaired hepatic uptake of lactate, but the mechanism was not clear. Uptake of lactate by the liver occurs by a membrane-associated, pH-dependent, antiport system known as the monocarboxylate transporter. In the hepatocyte, lactate can then be metabolized by oxidative phosphorylation or converted to glucose in the cytosol. In the present study, we examined (1) whether hepatic mitochondrial dysfunction accounted for decreased uptake of lactate in a canine model of Pseudomonas aeruginosa SS, (2) whether norepinephrine (NE) treatment by increasing mean arterial pressure (MAP) could improve mitochondrial dysfunction and LA in this model, and (3) whether gentisic acid sodium salt (GSS), a novel phenolic compound, was superior to NE in these effects.
In anesthetized/ventilated dogs, we infused the bacteria over ~10 h and measured hemodynamics in various treatment groups (see below). We then euthanized the animal and isolated the hepatic mitochondria. We measured hepatic mitochondrial oxygen consumption rates using the novel Seahorse XF24 analyzer under conditions that included: basal respiration, after the addition of adenosine- diphosphate to produce coupled respiration, and after the addition of a protonophore to produce maximal respiration.
We found that in the septic control group, mean arterial pressure decreased over the course of the study, and that mitochondrial dysfunction developed in which there was a reduction in maximal respiration. Whereas both NE and GSS treatments reversed the reduction in mean arterial pressure and increased maximal respiration to similar extents in respective groups, only in the GSS group was there a reduction in LA.
Hepatic mitochondrial dysfunction occurs in SS, but does not appear to be required for the development of LA in SS, since NE improved mitochondrial dysfunction without reversing LA. GSS, a phenolic compound restored mean arterial pressure, mitochondrial dysfunction, and LA in SS. This reduction in LA may be independent of its effect on improving hepatic mitochondrial function.
- Lactic acidosis
- Electron transport chain
- Septic shock
- Gentisic acid
The development of lactic acidemia (LA) in septic shock (SS) is associated with an ominous prognosis . Blood concentrations of lactate depend on its rate of production and utilization by various organs . Uptake of lactate by the liver occurs by means of a membrane-associated, pH-dependent, bidirectional facilitative antiport transport system known as the monocarboxylate transporter. Once transported into the hepatocyte, lactate can be converted into glucose by the gluconeogenic pathway or can be converted to pyruvate to enter the mitochondria to be metabolized to CO2 and water. The accumulation of lactate is usually associated with acidosis which may reflect ATP hydrolysis, extracellular transport of protons, among other mechanisms [1–8]. Hepatic mitochondrial dysfunction has been postulated as an explanation for the development of LA in SS, although extra-hepatic mechanisms also contribute [8–16]. In mitochondria, pyruvate undergoes conversion to acetyl CoA after which oxidative phosphorylation occurs. In this process, electrons are transferred primarily by reduced nicotinamide adenine dinucleotide (NADH) to mitochondrial complexes I, III, and IV to generate a proton (H+) gradient (the proton motive force; pmf) across the mitochondrial inner membrane. The free energy accumulated as the pmf is then used to drive ATP synthesis through the F1FoATP synthase activity (Complex V) allowing protons to return to the mitochondrial matrix [12, 13].
In the literature, the variable reports pertaining to hepatic mitochondrial dysfunction in SS may be a consequence of the different methodology and experimental protocols that were used in the different studies. The recent development of the Seahorse XF24 extracellular flux analyzer that we used in the present study allows for precise measurements of mitochondrial oxygen consumption under various conditions and has not previously been used to investigate hepatic mitochondrial dysfunction in SS (see Methods) .
Based on the numerous questions raised in the literature about the pathogenesis of LA in SS, we used a canine model in the present study to address the following questions. We first wanted to determine whether hepatic mitochondrial dysfunction evolved in this model and whether hepatic mitochondrial dysfunction could explain the development of LA that occurred. Secondly, we determined whether the finding of hepatic mitochondrial dysfunction in this model could be related to the accompanying systemic hypotension that develops in which we administered the vasopressor norepinephrine (NE) to reverse hypotension . Thirdly, we previously showed that select phenolic compounds (see further below and Discussion) have unique physiological properties in our sepsis models, likely attributable to their antioxidant capabilities, in which they are able to reverse the systemic vasodilation and hence the low mean blood pressure (MAP) that develops in these models [19, 20]. In preliminary experiments, we found that gentisic acid sodium salt (GSS), could not only reverse the low MAP that occurs in our sepsis model, but could also decrease blood lactate concentrations. GSS contains two hydroxyl moieties attached to the benzoic acid ring (2,5-dihydroxybenzoic acid sodium salt) [21, 22]. In the present study, we compared the efficacy of GSS on systemic hemodynamics, LA, and hepatic mitochondrial function in our canine model with those of NE to determine whether GSS could be used as a new treatment of cardiovascular collapse and LA in SS.
The University Animal Care Committee approved these canine experiments which conform with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No 85-23, 1996) . The protocol reference number is 13-046/1/2 (AC 10865).
In this study, we used a bacteremic model of Pseudomonas aeruginosa as previously described  to measure hepatic mitochondrial function and LA under conditions in which there was an intense inflammatory response. In this protocol, we infused ~1010 colony forming units/h of P. aeruginosa (ATCC 27853) mixed in normal saline solution over the duration of the study, while in the non-septic groups, we administered normal saline solution as a placebo over a similar time frame (see groups below). Over the course of the experiment, we studied the animals (18 to 26 kg) under sufentanil citrate (0.05–0.3 ug/kg/min) and midazolam (5 μg/kg/min) anesthesia, in which the animals were ventilated while receiving 100 % oxygen to maintain arterial around PO2 ~ 400 mmHg. We increased the ventilator rate over the course of the study to attenuate the development of the metabolic acidosis that is observed in this model .
To measure hemodynamic parameters, we inserted two vascular catheters under sterile conditions as previously described . We connected the catheters to respective pressure transducers (Cobe, Argon) that were referenced relative to the left atrium and that were connected to a chart recorder (Astro-Med, W Warwick, RI). To measure MAP, we inserted a polyethylene catheter into the right femoral artery, while to measure pulmonary vascular pressures, we inserted a Swanz-Ganz catheter (Edwards Lifesciences, Irvine, CA) by percutaneous techniques through the right jugular vein. From the Swanz-Ganz catheter, we obtained measurements of pulmonary arterial pressure (Ppa), wedge pressure (Pwp), and right atrial pressure (Rap), heart rate (HR) as well as determinations of thermodilution cardiac output (CO).
From the hemodynamic measurements, we calculated systemic vascular resistance (SVR) from [(MAP-Rap)/CO)*80]. We normalized measurements of CO and organ oxygen delivery (DO2) to body weight. We calculated oxygen delivery (DO2) from CO x Hb x 1.34 ml oxygen per gram of Hb, since Hb was 100 % saturated at a PO2 of ~400 mmHg. From the arterial catheter and distal port of the Swanz-Ganz catheter, we also took arterial and mixed venous blood samples, respectively, for analyses of PO2, PCO2, and pH.
In addition, we placed another polyethylene catheter into the left jugular vein, also by percutaneous techniques, for infusion of the bacteria and intravenous fluids and for obtaining blood chemistry and hematological samples. Since the baseline Pwp found in this model usually averages ≈ 10 mmHg, we infused normal saline solution as necessary to maintain Pwp relatively constant over the duration of this study. Additionally, we obtained blood samples in each condition (see further below) that included monitoring of serum liver function tests, troponin, our index of myocardial damage, lactate concentrations, hematocrit (Hct) and WBC, among others. The Clinical Chemistry Laboratory at the Health Sciences Centre performed these clinical laboratory tests.
We included five groups of animals in this study. These groups included a septic control group, a non-septic control group, a norepinephrine (NE) septic group, a gentisic acid sodium salt (GSS) septic group, and a GSS non-septic group. In each group, we made baseline measurements of hemodynamics and blood parameters after approximately 1-h period of stability. In the septic groups, after initiation of the bacterial infusion, we repeated the measurements in the septic shock condition. We defined the septic shock condition as the interval at which MAP decreased to 60–65 mmHg, since this would mark the MAP at which vasopressors would often be started in the clinical condition . While the bacteria were still being administered, we started an infusion of NE in the NE septic group to return MAP to the ~ baseline value, while in an identical manner, we infused GSS in the gentisic septic group to maintain MAP comparable to the baseline value. We used the baseline value as the target MAP for NE and GSS to achieve, since this would be an easily identified end-point (see Discussion). In the septic control group, after the SS condition, we started an infusion of 5 % dextrose in water (D5W) at approximately 40 ml/h for the remainder of the study, since D5W was the diluent for both the NE and GSS treatments.
In the two non-septic groups, since the septic shock condition usually occurred ≈ 4.5 h after the start of bacterial infusion, we made measurements at comparable baseline and sham shock intervals in these groups. After the sham shock condition, we infused GSS mixed in D5W in the GSS non-septic group and infused D5W alone in the non-septic control group for the remainder of the study. In the GSS non septic group, we infused the GSS treatment at a comparable rate to that administered in the gentisic septic group.
In all groups, we then made post-treatment measurements at 3 and 5 h after completion of the septic shock/sham-shock determinations.
After completion of the in-vivo measurements, we administered sodium pentobarbital (110 mg/kg) to euthanize the animal. In a subset of animals of each group, we immediately harvested a piece of liver and isolated the mitochondria as described by Schnaitman and Greenawalt . Briefly, we minced the extracted liver in mitochondrial isolation buffer (MSHE) that includes 70 mM sucrose, 210 mM mannitol, 5 mM : 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 1 mM ethylene glycol tetraacetic acid (EGTA), and fatty acid free bovine serum albumin (BSA). We then disrupted the tissue using a drill-driven glass/Teflon dounce homogenizer. We centrifuged the homogenate three times, after which we re-suspended the final pellet in a minimal volume of MSHE + BSA and determined protein (mg/ml). We diluted the mitochondrial preparation in cold mitochondrial assay solution (MAS) that contained 70 mM sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1 mM EGTA, and BSA for plating directly onto the custom Seahorse 24-well culture dish (~20 μg mitochondrial protein/50 μl per well; see further below). After centrifugation of the plate and addition of appropriate substrates, we viewed the mitochondria under a microscope to ensure consistent adherence to the well. We then transferred the plate to the XF24 Analyzer for initiation of the protocol as described below .
Mitochondrial measurement of oxygen consumption rates (OCR)
To examine hepatic mitochondrial function in this model, we used a novel technology that is capable of measuring dynamic changes in mitochondrial function, not easily attainable by other technologies . The Seahorse XF24 extracellular flux analyser (Seahorse Bioscience, MA, USA) uses a piston to reversibly enclose a small volume (7 μl) above the mitochondria that can monitor oxygen uptake in that volume for 2–5 min, then raises the piston, allowing the bulk incubation medium (~1 ml) to re-equilibrate. The ability to make up to four additions during the experiment allows mitochondrial respiration to be measured under various metabolic conditions. This piece of equipment has never been used to measure mitochondrial function in SS.
In this protocol, we sequentially measured mitochondrial function under various metabolic conditions . To obtain basal OCR, we first added a substrate to the preparation that contained pyruvate (10 mM) and malate (2 mM). We then added ADP (adenosine- diphosphate; 4 mM) that allows ATP synthase to function, producing an increase in OCR (coupled OCR). When the ATP/ADP ratio approaches equilibrium, pmf rises, after which proton reentry through the synthase stops and respiration slows. We terminated coupled respiration by the addition of the ATP synthase inhibitor oligomycin (2.0 μM) where ATP recycling cannot contribute and there is a stable decrease in OCR. We then added the protonophore, FCCP (4 μM; carbonyl cyanide p-triflouromethoxy-phenylhydrazone). FCCP leads to uncoupled respiration in which we previously titrated the concentration of FCCP to yield a maximal effect. In mitochondria in which ATP synthase activity is a limiting factor, uncoupled respiration may be greater than coupled respiration. This indicates that the mitochondria have reached maximal respiration in uncoupled respiration in which this respiration is not limited by ATP synthase activity (i.e., ATP accumulation feedbacks on OCR inhibition). We finally added rotenone (2 μM; R) and antimycin A (2 μM; AA) which are inhibitors of the electron transport chain (ETC) Complexes, I and III, respectively. When added to the mitochondrial preparation, these inhibitors produce a marked decline in mitochondrial respiration since the electron transport chain is inhibited.
With each treatment group, we obtained measurements of basal OCR, coupled OCR, maximal OCR, and spare respiratory capacity from (uncoupled respiration minus basal OCR). We obtained two measurements during each condition in which we reported the average of the two measurements in the analysis.
Determination of enzymatic activity of mitochondrial Complex IV (cytochrome c oxidase)
As part of our assessment of mitochondrial function, we also measured the enzymatic activity of hepatic mitochondrial Complex IV based on the rationale of Levy et al.  who considered that dysfunction of Complex IV was the most important determinant of abnormal mitochondrial function in SS. We determined Complex IV activity spectrophotometrically by a temperature-controlled Ultrospec 2100 ultraviolet-visible spectrophotometer (Biopharmacia Biotech, Uppsala, Sweden) . Complex IV activity was measured at 25 °C by monitoring the absorbance decrease of reduced cytochrome c at 550 nm. The reaction was started by addition of 40 μmol/l reduced cytochrome c into 50 mmol/l phosphate buffer containing 2.5 μg mitochondrial protein solubilized with 0.02 % laurylmaltoside.
For the hemodynamic measurements in the 5 treatment groups, we used a two-way ANOVA (split-plot) in which we normalized hemodynamic data (CO) to body weight. In this statistical analysis, there were five groups of animals (i.e., five levels of factor A comparison) and four different time periods (four levels of B comparison, i.e., baseline, septic shock condition and 3 and 5 h posttreatment; GB-Stat V8, Dynamic Microsystems, Inc., Silver Springs, MD). From the results of the ANOVA tables, we used a Student Newman Keuls (SNK) multiple comparison test to determine where there were differences observed among the groups at the specific time periods. In other analyses, when there was only one level of the B comparison present, we used a one way randomized ANOVA and SNK. We used two tail tests with significance of P < 0.05. Results are reported as mean ± 1 SD.
Among the five treatment groups, the time to reach the septic condition from baseline was not different, measuring (mean ± SD) 4.1 ± 1.3 h (n = 13) in the septic control group, 4.9 ± 1.8 h (n = 10) in the norepinephrine septic group, and 4.8 ± 2.4 h (n = 11) in the gentisic septic group. In the non-septic control group (n = 16) and the GSS non septic group (n = 5), we made measurements at 4.5 h post baseline in the sham-shock condition. In the five groups, there were no differences in the mean animal body weights, measuring 20.3 ± 2.7 kgs in the septic control group, 20.7 ± 1.7 kgs in the NE septic group, 22.3 ± 2.4 kgs in the gentisic septic group, 21.1 ± 2.7 kgs in the non-septic control group, and 23.6 ± 1.9 kgs in the GSS control group.
There were also no differences in the total amount of volume infused in the three septic groups over the course of the experiment, measuring 6 ± 1 l in the septic control group, 6 ± 1.6 l in the NE septic group, and 6.2 ± 1.7 l in the gentisic septic group. On the other hand, we administered significantly less fluid in the non-septic groups (P < .05) which measured 3.7 ± 1 l in the non septic and 3.4 ± 0.6 l in the GSS non septic group. At the time of autopsy, there was a large amount of ascites found in the septic groups which was not found in the non-septic groups and which accounted for the large positive fluid balance observed in the septic groups (see Discussion). All animals in each of the five groups survived the last measurement condition.
Hemodynamic measurements and laboratory results
The average dose of NE infused over the 5-h interval was 0.51 ± 0.22 μg/kg/min. In the gentisic septic group, the average dose of GSS infused over the same interval was 0.55 ± .29 mg/kg/min. The average infusion rate of GSS in the GSS non-septic group was 0.48 ± .008 mg/kg/min.
Systemic vascular resistances in the five groups (dynes S/cm5: mean ± SD)
3 h post
5 h post
Non-septic control group (n = 16)
2299 ± 603
2794 ± 1024+
2819 ± 1114
2829 ± 1007
Septic control group (n = 13)
2583 ± 803
1351 ± 374*
1745 ± 1037
2226 ± 1503
Gentisic septic group (n = 11)
2717 ± 605
1272 ± 695*
2767 ± 607
3234 ± 1013#
Norepinephrine septic group (n = 10)
2778 ± 526
1539 ± .375*
2573 ± 968
2767 ± 1063
Gentisic non-septic group (n = 5)
2740 ± 340
2416 ± 499
1798 ± 256
1866 ± 25
Cardiac indices in the five groups (l/min/kg: mean ± SD)
3 h post
5 h post
Non-septic control group (n = 16)
0.15 ± .03
0.15 ± .05
0.14 ± .04
0.13 ± .03
Septic control group (n = 13)
0.13 ± .04
0.17 ± .04
0.15 ± .07
0.11 ± .06
Gentisic septic group (n = 11)
0.12 ± .02
0.20 ± .08*+
0.12 ± .03
0.11 ± .04
Norepinephrine septic group (n = 10)
0.12 ± .02
0.15 ± .03
0.14 ± .03
0.14 ± .04
Gentisic non-septic group (n = 5)
0.12 ± .02
0.13 ± .02
0.16 ± .04
0.16 ± .05
In addition, we found that HR increased in the three septic groups during bacterial infusion from a mean of about 60 bpm at baseline to about 120 bpm at the septic shock condition (Fig. 1b). In the gentisic septic group, this treatment caused a significant decrease in HR at 3 and 5 h post-treatment as compared with the other septic groups. As well, we found that troponin, our index of myocardial injury, increased in the NE septic group at the 5 h interval, while we did not observe this finding in the other septic groups (see Additional file 1: Figure S1).
Left ventricular filling pressures (Pwp) in the five groups (mmHg: mean ± SD)
3 h post
5 h post
Non-septic control group (n = 16)
10.8 ± .1.6
12.8 ± 1.8*%
13.8 ± 2.1*%
13.9 ± 1.8!
Septic control group (n = 13)
10.7 ± 1.1
8.8 ± 1.6*
9.4 ± 1.4#
9.3 ± .1.4#
Gentisic septic group (n = 11)
10.2 ± 1.6
9.3 ± 2.6
11 ± 2.6
12 ± .2.9*
Norepinephrine septic group (n = 10)
10.0 ± .2
9.0 ± 1.6
10.2 ± 2.8
10.1 ± 2.7#
Gentisic non-septic group (n = 5)
13.0 ± 2.6+
14.2 ± 3.7 %
14.2 ± 2.2 %
13.6 ± 4.2 %*
To determine the extent to which oxygen delivery might have affected the changes in lactate concentrations with the different treatments, we also calculated DO2 in the five groups (see Additional file 2: Table S1). We found that on the mean DO2 at the end of the study was lowest in the septic control group. In the NE septic group, NE treatment caused an increase in DO2 as compared with the septic control group and the gentisic septic group. In terms of the latter effect, this was most due to an increase in hemoglobin, since CO did not change (see Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5 and Additional file 7: Table S6). Ph at the end of the study was higher in the gentisic septic group, while mixed venous PO2 were not different among the groups. Changes in other laboratory parameters among the groups were small (see Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5 and Additional file 7: Table S6; see Discussion).
In addition, enzymatic activity of mitochondrial Complex IV significantly decreased in the septic control group (2.87 ± .73 μmol/min/mg protein) as compared with the non septic control group (4.55 ± .98) (P < .01), while the values in the gentisic septic group, NE septic group, and GSS non septic group were 3.68 ± .59, 3.89 ± .33, 3.01 ± .66, and 2.44 ± .63, respectively. These results were not different among the groups (see Discussion).
We designed this study to address several questions. One objective was to determine whether hepatic mitochondrial dysfunction developed in this model of SS. To this effect, we showed that after approximately 10 h of bacteremia in this model, there was evidence that mitochondrial dysfunction had evolved. There was a significant reduction in maximal respiration found in the septic control group, while basal respiration and mitochondrial Complex IV enzymatic activity also appeared depressed. Coupled respiration did not decline. In the literature, the question of whether mitochondrial dysfunction develops in SS has been debated [16, 25, 26]. Although the explanation for differences in the literature is not clear and may be a consequence of the diverse models and methodologies used, most of the previous studies have concentrated either on coupled respiration (often termed State III) or the ratio of State III to State IV (in which oligomycin is added to the preparation) as their primary index of mitochondrial function. In contrast, our results demonstrate that uncoupled, maximal respiration may be a more sensitive parameter to reflect mitochondrial dysfunction in sepsis. In SS, because of the high metabolic energy demands that occur, hepatic mitochondrial ATP may be utilized as quickly as it is formed. Since there would be no feedback of ATP on inhibiting ATP synthase activity, uncoupled maximal respiration may be a more sensitive parameter of the mitochondrial dysfunction that occurs in patients in septic shock.
Another objective of this study was to determine whether NE treatment could reverse hepatic mitochondrial dysfunction in septic shock, since NE is often administered to increase blood pressure in the clinical condition. We found that in the NE septic group, NE resulted in an augmentation of maximal OCR to an extent comparable to that observed in the non-septic control group. In the literature, the effect of NE on mitochondrial function in sepsis has been controversial. Regueira and colleagues  found that in an endotoxemic pig model, administration of NE was associated with an improvement of hepatic mitochondrial respiration and concluded that this effect was probably mediated by a direct effect of NE on liver cells. On the other hand, in a fecal model of peritonitis in pigs, Vuda, and colleagues  did not find that NE improved mitochondrial function when they measured the in vitro effect of NE on respiratory efficiency of Complex I and Complex II of hepatic cells taken after prolonged exposure to sepsis.
NE treatment could prevent mitochondrial dysfunction by increasing hepatic oxygen delivery, thereby preventing oxidant damage produced by ischemic hypoxia, or by an intrinsic effect. NE has been shown to cause an increase in calcium transport into the mitochondrial matrix . Calcium can stimulate three different dehydrogenases of the citric acid cycle increasing the substrate availability of NADH to the respiratory chain that could lead to an increase in mitochondrial respiration. Although the present study does not elucidate the mechanism involved, we found that NE treatment resulted in an increase in DO2 in the NE septic group as compared with the septic control group (see Additional file 2: Table S1). In a previous study , we found that hepatic blood flow was well-maintained in a NE treated septic group as compared to an untreated septic group . Thus, an increase in oxygen delivery to the liver could have reversed any contribution of ischemic hypoxia to the mitochondria and prevented mitochondrial oxidant damage in the NE treated septic group [7–9]. Although this study does not delineate the mechanism involved, the fact that NE can reverse mitochondrial dysfunction in SS provides a rationale for its use in the treatment in the clinical situation.
Despite the fact that NE reversed hepatic mitochondrial dysfunction in the NE septic group, our results importantly show that this effect did not lead to an attenuation of LA. Thus, hepatic mitochondrial dysfunction is not necessary for the development of LA in SS. In the NE septic group, we observed that mean blood lactate concentration increased over the course of the study, such that at the 5-h measurement period, serum lactate was not different from that observed in the septic control group. In a previous study, we did not find that NE infusion altered hepatic lactate extraction, hepatic blood flow, or splanchnic lactate production in a similar animal model , although it is possible that the high lactate concentration found in the NE septic group in the present study was related to increased lactate production from extra-hepatic sources, such as skeletal muscle . Nevertheless, although there may be a variety of extra hepatic sources of lactate that contribute in sepsis under various conditions, we previously observed that the canine liver could efficiently metabolize very large quantities of lactate during lactate loading under non septic conditions . One would expect therefore that this very large reserve capacity of the liver would be able to overcome any contribution of lactate from an extra-hepatic source maintaining lactate concentrations low. Taken together, these findings suggest that hepatic impairment of lactate metabolism in SS may also reflect a non-mitochondrial mechanism, and that LA may occur in SS despite the finding of normal hepatic mitochondrial function. Whereas it is likely that hepatic mitochondrial dysfunction contributes to LA in SS under conditions when MAP decreases to a value low enough to cause severe mitochondrial hypoxia, we believe that an impairment of hepatic metabolism of lactate may also occur through other mechanisms in this condition, such as those that involve accelerated glycolysis  or impaired gluconeogenesis  (see further below).
In contrast to NE treatment, GSS was capable of improving the three most important parameters measured in this study, namely MAP, hepatic mitochondrial dysfunction and LA. GSS contains two hydroxyl moieties attached to the benzoic acid ring (2,5-dihydroxybenzoic acid sodium salt) and is a breakdown product of aspirin [21, 22]. GSS has potent antioxidant properties that might account for its greater beneficial effect than NE on mitochondrial function in this model. In the present study, not only did GSS result in an increase in maximal OCR as compared with the septic control group, but GSS caused a marked increase in coupled respiration and an increase in basal respiration. Whereas there was only a trend for GSS to increase mitochondrial Complex IV by enzymatic measurements, we think that measurements of OCR by the Seahorse Instrument provide a much more sensitive indication of mitochondrial function than does the assessment of mitochondrial enzymatic activity of the different complexes. The electron transport chain comprises multiple enzymatic complexes of which one or all may be compromised in SS. Brealey and colleagues  found that Complex IV activity was preserved in a long-term rodent model of sepsis, while activity of Complex I decreased. We measured Complex IV activity in this model based on the work of Levy et al.  and did not measure Complex I activity. Different results in the literature may reflect the various preparations and models that were used. However, an advantage of the Seahorse Instrument is that it gives an overall functional assessment of the entire electron transport chain in which the functionality of whole chain is assessed, while the significance of small reductions in enzymatic activity of the different complexes in terms of their role in reducing OCR may be difficult to assess.
In the gentisic septic group, the mechanism by which GSS enhanced mitochondrial function was most likely related to GSS’s antioxidant effects that could lead to an increase in coupled respiration by enhanced transfer of ATP out of the cell by adenine nucleotide translocase. This could lead to less feedback inhibition of respiration by ATP, such that mitochondrial coupled respiration would be higher in the gentisic septic group. It is also important to note that not all phenolic compounds have the capacity to reduce LA in this SS model, since we did not find this effect to occur when we administered ethyl gallate in a similar manner . Ethyl gallate has a structure similar to that of GSS, but has three hydroxyl moieties and different physical properties, in which the pKa of GSS is higher than ethyl gallate which may be important in the phenol’s ability to modify lactate metabolism in SS.
The mechanism by which GSS caused a reduction of LA is not clear. One possibility is that since GSS had a greater effect on coupled respiration than did NE, this could make oxidative phosphorylation supernormal leading to enhanced hepatic clearance of lactate by this mechanism. However, against this possibility is the fact that maximal, uncoupled respiration did not increase in the gentisic septic group, a finding of which would also be expected to occur in this instance. Nevertheless, there are other mechanisms to consider. One possibility is that GSS could have decreased splanchnic production of lactate, or alternatively could have increased hepatic uptake of lactate by mechanisms that are independent of mitochondrial function. For instance, this could occur by enhancing hepatic gluconeogenesis, or by reducing glycolysis, since both of the latter mechanisms have been reported in other conditions. For instance, in asthma, β-agonist effects have been shown to produce elevations in lactate by enhancing glycolysis even under non-hypoxemic conditions . On the other hand, in diabetes, metformin has been shown to suppress gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase, which leads to enhanced lactate production in the cytosol . The extent to which each of these mechanisms could play a role in GSS’s effect is not yet clear, but is worthy of future investigation.
In this study, we recognize moreover that in terms of the animal model used, there are a number of methodological issues that need to be addressed. We administered a high concentration of NE in the NE septic group, since, in the design of this study, we wanted to return MAP to the baseline value. We chose the latter high end-point to clearly demonstrate a change in MAP between the shock condition and the 5-h measurement with NE treatment. On the other hand, in clinical medicine, a much lower MAP end-point would be chosen with a corresponding lower concentration of NE. Whether a lower rate of NE infusion would provide a similar beneficial effect on hepatic mitochondrial function is not clear at this time.
Moreover, in the design of this study, although we attempted to keep Pwp close to the baseline value, there were slight changes in Pwp that occurred over the course of the study in the five groups. In the non-septic groups, we needed to constantly infuse intravenous volume to administer the anesthetic agents, so that Pwp rose slightly over the course of the study and there was net intravascular fluid retention. On the other hand, in the septic groups, particularly from the baseline to shock condition, there was a lot of third spacing (i.e., ascites was often found at autopsy) which tended to reduce Pwp. After the shock condition, however, when the vasoactive agents were added in the gentisic septic group and the NE septic group, there were increases in afterload which led to increases in Pwp. While intravenous fluids could easily be given when the Pwp was low, we did not want to phlebotomize that animal if the Pwp rose, because hemodynamic instability often follows this procedure . Overall, however, the changes in Pwp were relatively small (see Table 3), and moreover, we do not think these changes would affect the hemodynamic findings to a significant extent. At a Pwp ~10 mmHg, the left ventricle is well-filled and the left ventricular diastolic volume pressure relationship is relatively flat with little changes in ventricular volume for a given change in Pwp . This finding would limit any alterations in CO that would occur under the variations in Pwp found in the present study.
Finally, we noticed small changes in the blood chemistries in the non-septic control groups over the course of the experiment, particularly in creatine kinase which was probably related to some rhabdomyolysis because we positioned the animals in the supine position and did not turn the animal over the 10-h course of the study (see Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5 and Additional file 7: Table S6). To some extent, this may have produced skeletal muscle damage leading to mild renal dysfunction. However, the changes in blood chemistries in the non-septic groups were markedly less than those found in the septic groups, so that we do not think that these small changes in blood chemistries affected the major conclusions of the study.
In a canine model of SS, we showed that, hepatic mitochondrial dysfunction evolved over the course of sepsis in which the predominant finding observed was a reduction in maximal OCR. Although NE was able to reverse hepatic mitochondrial dysfunction in SS, this effect was not associated with an improvement in LA. Thus, hepatic mitochondrial dysfunction is not a requirement for the development of LA in this SS model. In contrast, GSS had a greater effect than NE on reversing hepatic mitochondrial dysfunction and additionally caused a reduction in LA. As compared with NE, HR with GSS were lower, despite similar increases in MAP with the two treatments. Among other possibilities, we speculate that GSS could reduce LA by increasing hepatic uptake of lactate either by decreasing the rate of hepatic glycolysis or by increasing hepatic gluconeogenesis. Although the relationship between animal models and the human condition must be considered cautiously, we propose that GSS may be a novel therapy for the treatment for LA and cardiovascular collapse in SS.
AA, antimycin A; ADP, adenosine diphospate; ANOVA, analysis of variance; ATP, adenosine triphosphate; BSA, bovine serum albumin; CO, cardiac output; D5W, 5 % dextrose in water; DO2, oxygen delivery; EGTA, ethylene glycol tetraacetic acid; ETC., electron transport chain; FCCP, carbonyl cyanide p-triflouromethoxy-phenylhydrazone; GSS, gentisic acid sodium salt; H+, proton; Hb, hemoglobin; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid); HR, heart rates; LA, lactic acidosis; MAP, mean arterial pressure; MAS, mitochondrial assay solution; MD, myocardial depression; MSHE, mitochondrial isolation buffer; NADH, nicotinamide adenine dinucleotide; NE, norepinephrine; OCR, oxygen consumption rate; OH−, hydroxyl ion; pmf, proton motive force; Ppa, mean pulmonary artery pressure; Pwp, mean pulmonary wedge pressure; R, rotenone; Rap, mean right atrial pressure; ROS, reactive oxygen species; SNK, Student Newman Keuls multiple comparison test; SS, septic shock; SVR, systemic vascular resistance
This study was supported by the Biology of Breathing Group and the Children’s Hospital Research institute of Manitoba.
JG and KK performed the in vivo experiments. ZQC and SKRC performed the mitochondrial experiments, while SKRC and PF contributed to the data collection, analysis of the mitochondrial experiments, and interpretation of the manuscript. SM contributed to the design, data collection, analysis, and interpretation of the manuscript. All authors read and approved the final manuscript.
Drs Steven Mink and Paul Fernyhough have applied for a patent for the use of gentistic acid sodium salt in the treatment of hemodynamic collapse in septic shock. None of the other authors have any competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Gutierrez G, Wulf ME (1996) Lactic acidosis in sepsis: a commentary. Intensive Care Med 22:6–16View ArticlePubMedGoogle Scholar
- Vernon C, LeTourneau JL (2010) Lactic acidosis: recognition, kinetics, and associated prognosis. Critical Care Clin 26:255–283View ArticleGoogle Scholar
- Chrusch C, Bands C, Bose D, Li X, Jacobs H, Duke K, Bautista E et al. (2000) Impaired hepatic extraction and increased splanchnic production contribute to lactic acidosis in canine sepsis. Am J Respir Crit Care Med 161:517–526View ArticlePubMedGoogle Scholar
- Poole RC, Halestrap AP (1993) Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol 264(Cell Physiol 33):C761–C782PubMedGoogle Scholar
- Halestrap AP, Wilson MC (2012) The monocarboxylate transporter family-role and regulation. Life 64:109–119PubMedGoogle Scholar
- Halestrap AP (2013) Monocarboxylic acid transport. Compr Physiol 3:1611–1643, American Physiological SocietyView ArticlePubMedGoogle Scholar
- Galley HF (2010) Bench-to-bedside review: Targeting antioxidants to mitochondria in sepsis. Crit Care 14:230PubMedPubMed CentralGoogle Scholar
- Galley HF (2011) Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 107:57–64View ArticlePubMedGoogle Scholar
- Crouser ED (2004) Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 4:729–741View ArticlePubMedGoogle Scholar
- Levy RJ, Deutschman CS (2007) Cytochrome c oxidase dysfunction in sepsis. Crit Care Med 35:S468–S475View ArticlePubMedGoogle Scholar
- Muravchick S, Levy RJ (2006) Clinical implications of mitochondrial dysfunction. Anesthesiology 105:819–837View ArticlePubMedGoogle Scholar
- Brand MD, Nicholls DG (2011) Assessing mitochondrial dysfunction in cells. Biochem J 435:297–312View ArticlePubMedPubMed CentralGoogle Scholar
- Barrientos A, Fontanes F, Diaz F (2009). Evaluation of the mitochondrial respiratory chain and oxidative phosphorylation system using polarography and spectrophotometric enzyme assays. Curr Protoc Hum Genet. Chapter 19:Unit19.3. doi: 10.1002/0471142905.hg1903s63
- Brealey D, Brand M, Hargreaves I, Healtes S, Land J, Smolenski R et al. (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360:219–223View ArticlePubMedGoogle Scholar
- Japiassu AM, Paula A, Santiago A, da d’Vila JoanaCosta P, Garcia- Soua Luiz F, Galina A et al (2011) Bioenergetic failure of human peripheral blood monocytes in patients with septic shock is mediated by reduced F1Fo adenosine-5-triphosphate synthase activity. Crit Care Med 39:1056–1063View ArticlePubMedGoogle Scholar
- Jeger V, Djafarazadeh S, Jakob SM, Takala J (2013) Mitochondrial function in sepsis. Eur J Clin Invest 43:532–542View ArticlePubMedGoogle Scholar
- Roy Chowdhury SK, Smith DR, Saleh A, Schapansky J, Marquez A, Gomes S et al. (2012) Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 135:1751–1766View ArticlePubMedPubMed CentralGoogle Scholar
- Dellinger RP, Levy MM, Carlet JM et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med 36:296–327View ArticlePubMedGoogle Scholar
- Mink SN, Jacobs H, Gotes J, Kasian K, Cheng ZQ (2011) Ethyl gallate, a scavenger of hydrogen peroxide that inhibits lysozyme-induced hydrogen peroxide signaling in vitro, reverses hypotension in canine septic shock. J Appl Physiol 110:359–374View ArticlePubMedGoogle Scholar
- Gotes J, Jacobs KK, Cheng ZQ, Mink SN (2012) Benefits of ethyl gallate vs norepinephrine in the treatment cardiovascular collapse in Pseudomonas aeruginosa septic shock in dogs. Crit Care Med 40:560–572View ArticlePubMedGoogle Scholar
- Sroka Z, Cisowski W (2003) Hydrogen peroxide scavenging, antioxidant and anti radical activity of some phenolic acids. Food Chem Toxicol 41:753–758View ArticlePubMedGoogle Scholar
- Hutt AJ, Caldwell J, Smith RL (1982) The metabolism of [carboxyl-14C]aspirin in man. Xenobiotica 12:601–610View ArticlePubMedGoogle Scholar
- National Institutes of Health (1996) Guide for the care and use of laboratory animals. National Institutes of Health, Bethesda, MD, NIH Publication No 85–23Google Scholar
- Schnaitman C, Greenawalt JW (1968) Enzymatic properties of the inner and outer membranes of rat liver mitochondria. J Cell Biol 38:158–175View ArticlePubMedPubMed CentralGoogle Scholar
- Vuda M, Brander L, Schroder R, Jakob S, Takala J, Djafarzadeh S (2011) Effects of catecholamines on hepatic and skeletal muscle mitochondrial respiration after prolonged exposure to faecal peritonitis in pigs. Innate Immunity 18:217–230View ArticlePubMedGoogle Scholar
- Gellerich FN, Trumbeckaite S, Opalka JR, Gellerich JF, Chen Y, Neuhof C et al. (2002) Mitochondrial dysfunction in sepsis: evidence from bacteraemic baboons and endotoxaemic rabbits. Biosci Rep 22:99–113View ArticlePubMedGoogle Scholar
- Regueira T, Banziger B, Djafarzadeh S, Brandt S, Gorrasi J, Takala J et al. (2008) Norepinephrine to increase blood pressure in endotoxaemic pigs is associated with improved hepatic mitochondrial respiration. Crit Care 12:R88View ArticlePubMedPubMed CentralGoogle Scholar
- Binet A, Claret M (1983) Alpha-adrenergic stimulation of respiration in isolated rat hepatocytes. Biochem J 283:867–873View ArticleGoogle Scholar
- Levy B, Gibot S, Franck P, Bollaert PE (2005) Relation between muscle Na+ K+ ATPase activity and raised lacatate concentrations in septic shock: a prospective study. Lancet 365:871–875View ArticlePubMedGoogle Scholar
- Stratakos G (2002) Transient lactic acidosis as a side effect of inhaled salbutamol. Chest 122:385–386View ArticlePubMedGoogle Scholar
- Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA et al. (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510:542–546View ArticlePubMedPubMed CentralGoogle Scholar
- Brealey D, Karyampundi S, Jacques TS, Novelli M, Stidwill R, Taylor V et al (2003) Miotchondiral dysfunction in a long-term rodent model of sepsis and organ failure. Am J Physiol Regul Integr Com Physiol 286:R491–R497View ArticleGoogle Scholar
- Mink SN, Jha P, Wang R, Yang J, Bose D, Jacobs H et al. (1995) Effect of continuous arteriovenous hemofiltration combined with systemic vasopressor therapy on depressed left ventricular contractility and tissue oxygen delivery in canine Escherichia coli sepsis. Anesthesiology 83:178–190View ArticlePubMedGoogle Scholar
- Gomez A, Unruh H, Mink SN (1993) Altered left ventricular chamber stiffness and isovolumic relaxation in dogs with chronic pulmonary hypertension caused by emphysema. Circulation 87:247–260View ArticlePubMedGoogle Scholar